Charlene Choo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charlene Choo has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Aldave
Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA
4 shared publications - Jessica G. Shantha
Francis I. Proctor Foundation, University of California, San Francisco, CA, USA
3 shared publications Steven Yeh
3 shared publicationsThuy Doan
3 shared publicationsArmin Hinterwirth
From the Francis I. Proctor Foundation (J.G.S., W.A., D.Y., L.Z., C.C., K.D.S., A.H., T.P., B.F.A., J.G., N.R.A., T.M.L., T.D.), University of California, San Francisco, California, USA
2 shared publicationsDaisy Yan
From the Francis I. Proctor Foundation (J.G.S., W.A., D.Y., L.Z., C.C., K.D.S., A.H., T.P., B.F.A., J.G., N.R.A., T.M.L., T.D.), University of California, San Francisco, California, USA
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in The Lancet Microbe
Assessment of Ebola virus persistence in vitreous fluid of Ebola virus disease survivors with vitreoretinal disease in Sierra Leone: a cross-sectional study
- 18 November 2026
- Published by Elsevier in The Lancet Microbe
Open AccessAssessment of Ebola virus persistence in vitreous fluid of Ebola virus disease survivors with vitreoretinal disease in Sierra Leone: a cross-sectional study
- 11 August 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 280, 154-168
Peripheral Macular Endothelial Dystrophy: Clinical, Histopathologic, Genetic and Functional Characterization
- 11 August 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 280, 154-168
Peripheral Macular Endothelial Dystrophy: Clinical, Histopathologic, Genetic and Functional Characterization
- Open Access
- 15 July 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 279, 100-109
The Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial
- 15 July 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 279, 100-109
Open AccessThe Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial
- 23 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 260-268
Practice Patterns, Diagnostic Utility, and Safety of Anterior Chamber Paracentesis
- 23 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 260-268
Practice Patterns, Diagnostic Utility, and Safety of Anterior Chamber Paracentesis
- 9 August 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (1) , 70-75
Deep sequencing as a diagnostic tool in patients with suspected primary vitreoretinal lymphoma
Purpose: To compare the diagnostic utility of metagenomic deep sequencing (MDS) to cytology, flow cytometry and gene rearrangement by PCR in ocular samples of patients with suspected vitreoretinal lymphoma (VRL). Methods: Patients with suspected VRL underwent ocular sampling of one or both eyes at the Emory Eye Center from September 2017 to June 2022. Ocular samples were evaluated with MDS and conventional diagnostics. MDS was performed at the Ralph and Sophie Heintz Laboratory at the F.I. Proctor Foundation. Relevant demographic and clinical data were retrospectively collected from medical records. Patients were diagnosed with VRL based on clinical assessment and conventional diagnostic testing. Results: This study included 13 patients with suspected VRL who underwent diagnostic vitrectomy, including 1 patient who had an additional subretinal biopsy. Six patients (46.2%) were diagnosed with VRL. Among patients diagnosed with VRL, MDS detected pathogenic mutations in 5 out of 6 patients (83.3%) while cytology was positive for VRL in 4 out of 6 patients (66.7%), flow cytometry in 4 out of 4 patients (100.0%) and PCR in 4 out of 4 patients (100.0%). MDS detected mutations in MYD88 in 2 out of 6 patients diagnosed with VRL. In 7 patients (53.8%) not diagnosed with VRL, MDS detected pathogenic lymphoma mutations in 2 patients (28.6%). Discussion: MDS detected pathogenic mutations in five out of six patients diagnosed with VRL, including in two patients with negative cytology, demonstrating its potential to improve diagnostic rates of VRL as an adjunctive test.
- 9 August 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (1) , 70-75
Deep sequencing as a diagnostic tool in patients with suspected primary vitreoretinal lymphoma
Purpose: To compare the diagnostic utility of metagenomic deep sequencing (MDS) to cytology, flow cytometry and gene rearrangement by PCR in ocular samples of patients with suspected vitreoretinal lymphoma (VRL). Methods: Patients with suspected VRL underwent ocular sampling of one or both eyes at the Emory Eye Center from September 2017 to June 2022. Ocular samples were evaluated with MDS and conventional diagnostics. MDS was performed at the Ralph and Sophie Heintz Laboratory at the F.I. Proctor Foundation. Relevant demographic and clinical data were retrospectively collected from medical records. Patients were diagnosed with VRL based on clinical assessment and conventional diagnostic testing. Results: This study included 13 patients with suspected VRL who underwent diagnostic vitrectomy, including 1 patient who had an additional subretinal biopsy. Six patients (46.2%) were diagnosed with VRL. Among patients diagnosed with VRL, MDS detected pathogenic mutations in 5 out of 6 patients (83.3%) while cytology was positive for VRL in 4 out of 6 patients (66.7%), flow cytometry in 4 out of 4 patients (100.0%) and PCR in 4 out of 4 patients (100.0%). MDS detected mutations in MYD88 in 2 out of 6 patients diagnosed with VRL. In 7 patients (53.8%) not diagnosed with VRL, MDS detected pathogenic lymphoma mutations in 2 patients (28.6%). Discussion: MDS detected pathogenic mutations in five out of six patients diagnosed with VRL, including in two patients with negative cytology, demonstrating its potential to improve diagnostic rates of VRL as an adjunctive test.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Eye Banking and Corneal Transplantation
- Vol. 2 (4) , e0017
The Effect of SkQ1 on the Oxidative Stress and Inflammatory Responses in Corneal Endothelial Cells During Ex Vivo Expansion
Purpose: The purpose of this study was to characterize the oxidative stress and inflammatory responses in ex vivo corneal endothelial cells (evCEnC) during expansion and assess the impact of SkQ1, an antioxidant and anti-inflammatory compound, on measures of oxidative stress and inflammation. Methods: A CEnC line (HCEnC-21T) was cultured in media supplemented with varying SkQ1 concentrations to determine the optimal SkQ1 dose range of toxicity and protective effect on CEnC exposed to acute oxidative stress. The impact of SkQ1 treatment on intracellular free radical (IFR) levels, NRF2-mediated oxidative stress response, and NFkB-mediated inflammatory response was determined at each passage of evCEnC isolated from donor corneas and cultured in SkQ1-supplemented and untreated media. Results: HCEnC-21T cultured in media supplemented with ≤250 nM SkQ1 retained over 95% cell viability compared with untreated cells. SkQ1 provided oxidative stress protection to HCEnC-21T in a dose-dependent manner up to 500 nM. In evCEnC, 50 nM and 250 nM SkQ1 supplementation significantly reduced IFR levels across passages 0 to 3 (P-values of 0.015 and 0.023, respectively) and 50 nM SkQ1 supplementation led to decreased levels of active NRF2 in evCEnC at passage 2. However, media supplementation with SkQ1 (50 nM and 250 nM) did not alter NFkB activation at any passage. Conclusions: SkQ1 media supplementation provides oxidative stress protection to HCEnC-21T in a dose-dependent manner and decreases IFR levels and NRF2 activation in evCEnC during expansion at concentrations that do not negatively affect CEnC viability. These findings indicate that SkQ1 supplementation may increase the expansion potential of evCEnC.
- 1 December 2023
- Published by Wolters Kluwer Health in Eye Banking and Corneal Transplantation
- Vol. 2 (4) , e0017
Open AccessThe Effect of SkQ1 on the Oxidative Stress and Inflammatory Responses in Corneal Endothelial Cells During Ex Vivo Expansion
Purpose: The purpose of this study was to characterize the oxidative stress and inflammatory responses in ex vivo corneal endothelial cells (evCEnC) during expansion and assess the impact of SkQ1, an antioxidant and anti-inflammatory compound, on measures of oxidative stress and inflammation. Methods: A CEnC line (HCEnC-21T) was cultured in media supplemented with varying SkQ1 concentrations to determine the optimal SkQ1 dose range of toxicity and protective effect on CEnC exposed to acute oxidative stress. The impact of SkQ1 treatment on intracellular free radical (IFR) levels, NRF2-mediated oxidative stress response, and NFkB-mediated inflammatory response was determined at each passage of evCEnC isolated from donor corneas and cultured in SkQ1-supplemented and untreated media. Results: HCEnC-21T cultured in media supplemented with ≤250 nM SkQ1 retained over 95% cell viability compared with untreated cells. SkQ1 provided oxidative stress protection to HCEnC-21T in a dose-dependent manner up to 500 nM. In evCEnC, 50 nM and 250 nM SkQ1 supplementation significantly reduced IFR levels across passages 0 to 3 (P-values of 0.015 and 0.023, respectively) and 50 nM SkQ1 supplementation led to decreased levels of active NRF2 in evCEnC at passage 2. However, media supplementation with SkQ1 (50 nM and 250 nM) did not alter NFkB activation at any passage. Conclusions: SkQ1 media supplementation provides oxidative stress protection to HCEnC-21T in a dose-dependent manner and decreases IFR levels and NRF2 activation in evCEnC during expansion at concentrations that do not negatively affect CEnC viability. These findings indicate that SkQ1 supplementation may increase the expansion potential of evCEnC.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 323 (2) , G134-G143
Colonic mucosal microbiota is associated with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome
Mucosal microbiota differ significantly from fecal microbiota and may play a different role in the pathophysiology of irritable bowel syndrome (IBS). The aims of this study were to determine if the composition of mucosal microbiota differed between IBS, or IBS bowel habit (BH) subtypes, and healthy controls (HCs). Sigmoid colon mucosal biopsies were obtained from 97 Rome-positive patients with IBS (28% IBS-constipation, 38% IBS-diarrhea, 24% IBS-mixed, and 10% IBS-unsubtyped) and 54 HCs, from which DNA was extracted. 16S rRNA gene sequencing and microbial composition analysis were performed. Group differences in α and β diversity and taxonomic level differences were determined using linear regression while controlling for confounding variables. IBS BH subtype was associated with microbial α diversity (P = 0.0003) with significant differences seen in the mucosal microbiota of IBS-constipation versus IBS-diarrhea (P = 0.046). There were no significant differences in α or β diversity in the mucosal microbiota of IBS versus HCs (P = 0.29 and 0.93, respectively), but metagenomic profiling suggested functional differences. The relative abundance of Prevotella_9 copri within IBS was significantly correlated with increased abdominal pain (r = 0.36, P = 0.0003), which has not been previously reported in IBS. Significant differences in the mucosal microbiota were present within IBS BH subtypes but not between IBS and HCs, supporting the possibility of IBS BH subtype-specific pathogenesis. Increased Prevotella copri may contribute to symptoms in patients with IBS. NEW & NOTEWORTHY Gut mucosal microbiota differs significantly from fecal microbiota in irritable bowel syndrome (IBS) and may play a different role in its pathophysiology. Investigation of colonic mucosal microbiota in the largest cohort of patients with IBS and healthy controls accounting for confounding variables, including diet demonstrated significant differences in mucosal microbiota between IBS bowel habit subtypes but not between IBS and healthy controls. In addition, the study reported gut microbiota is associated with abdominal pain in patients with IBS.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 323 (2) , G134-G143
Colonic mucosal microbiota is associated with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome
Mucosal microbiota differ significantly from fecal microbiota and may play a different role in the pathophysiology of irritable bowel syndrome (IBS). The aims of this study were to determine if the composition of mucosal microbiota differed between IBS, or IBS bowel habit (BH) subtypes, and healthy controls (HCs). Sigmoid colon mucosal biopsies were obtained from 97 Rome-positive patients with IBS (28% IBS-constipation, 38% IBS-diarrhea, 24% IBS-mixed, and 10% IBS-unsubtyped) and 54 HCs, from which DNA was extracted. 16S rRNA gene sequencing and microbial composition analysis were performed. Group differences in α and β diversity and taxonomic level differences were determined using linear regression while controlling for confounding variables. IBS BH subtype was associated with microbial α diversity (P = 0.0003) with significant differences seen in the mucosal microbiota of IBS-constipation versus IBS-diarrhea (P = 0.046). There were no significant differences in α or β diversity in the mucosal microbiota of IBS versus HCs (P = 0.29 and 0.93, respectively), but metagenomic profiling suggested functional differences. The relative abundance of Prevotella_9 copri within IBS was significantly correlated with increased abdominal pain (r = 0.36, P = 0.0003), which has not been previously reported in IBS. Significant differences in the mucosal microbiota were present within IBS BH subtypes but not between IBS and HCs, supporting the possibility of IBS BH subtype-specific pathogenesis. Increased Prevotella copri may contribute to symptoms in patients with IBS. NEW & NOTEWORTHY Gut mucosal microbiota differs significantly from fecal microbiota in irritable bowel syndrome (IBS) and may play a different role in its pathophysiology. Investigation of colonic mucosal microbiota in the largest cohort of patients with IBS and healthy controls accounting for confounding variables, including diet demonstrated significant differences in mucosal microbiota between IBS bowel habit subtypes but not between IBS and healthy controls. In addition, the study reported gut microbiota is associated with abdominal pain in patients with IBS.
- Open Access
- 22 March 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 43 (4) , 530-533
Confirmation of association of TGFBI p.Ser591Phe mutation with variant lattice corneal dystrophy
To provide the initial confirmation of the c.1772C>T (p.Ser591Phe) mutation in the transforming growth factor-β-induced (TGFBI) gene as being associated with variant lattice corneal dystrophy (LCD)...
- 22 March 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 43 (4) , 530-533
Open AccessConfirmation of association of TGFBI p.Ser591Phe mutation with variant lattice corneal dystrophy
To provide the initial confirmation of the c.1772C>T (p.Ser591Phe) mutation in the transforming growth factor-β-induced (TGFBI) gene as being associated with variant lattice corneal dystrophy (LCD)...
- 5 August 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 41 (6) , 779-781
Confirmation of PRDX3 c.568G>C as the Genetic Basis of Punctiform and Polychromatic Pre-Descemet Corneal Dystrophy
Purpose: The aim of this study was to report the results of screening peroxiredoxin 3 (PRDX3) and PDZ domain-containing protein 8 (PDZD8) in a previously unreported pedigree with punctiform and polychromatic pre-Descemet corneal dystrophy (PPPCD) to confirm that the PRDX3 mutation c.568G>C is the genetic basis of PPPCD. Methods: Ophthalmologic examination of the proband and her affected father was performed with slit lamp biomicroscopy. Saliva was collected from the proband as a source of DNA, after which screening for PRDX3 and PDZD8 was performed. Results: Slit lamp examination of the proband revealed polychromatic deposits diffusely distributed at the pre-Descemet level in both corneas and anterior subcapsular in the crystalline lens of both eyes. The proband's father also demonstrated diffuse pre-Descemetic polychromatic deposits in both eyes but no lenticular deposits. Screening of PRDX3 in the proband demonstrated the c.568G>C (p.Asp190His) variant previously associated with PPPCD and failed to identify any variants in PDZD8. Conclusions: We report the initial confirmation of PRDX3 as the genetic basis of PPPCD in a previously unreported pedigree and expand the phenotype of PPPCD to include polychromatic lenticular deposits.
- 5 August 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 41 (6) , 779-781
Confirmation of PRDX3 c.568G>C as the Genetic Basis of Punctiform and Polychromatic Pre-Descemet Corneal Dystrophy
Purpose: The aim of this study was to report the results of screening peroxiredoxin 3 (PRDX3) and PDZ domain-containing protein 8 (PDZD8) in a previously unreported pedigree with punctiform and polychromatic pre-Descemet corneal dystrophy (PPPCD) to confirm that the PRDX3 mutation c.568G>C is the genetic basis of PPPCD. Methods: Ophthalmologic examination of the proband and her affected father was performed with slit lamp biomicroscopy. Saliva was collected from the proband as a source of DNA, after which screening for PRDX3 and PDZD8 was performed. Results: Slit lamp examination of the proband revealed polychromatic deposits diffusely distributed at the pre-Descemet level in both corneas and anterior subcapsular in the crystalline lens of both eyes. The proband's father also demonstrated diffuse pre-Descemetic polychromatic deposits in both eyes but no lenticular deposits. Screening of PRDX3 in the proband demonstrated the c.568G>C (p.Asp190His) variant previously associated with PPPCD and failed to identify any variants in PDZD8. Conclusions: We report the initial confirmation of PRDX3 as the genetic basis of PPPCD in a previously unreported pedigree and expand the phenotype of PPPCD to include polychromatic lenticular deposits.